CFM
SGMT icon

Catalyst Funds Management’s Sagimet Biosciences SGMT Stock Holding History

Catalyst Funds Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.6K Buy
+13,900
New +$77.5K 0.01% 514
2024
Q4 		– Sell
-2,600
Closed -$7.2K – 1115
2024
Q3 		$7.2K Sell
2,600
-3,200
-55% -$9.86K ﹤0.01% 1221
2024
Q2 		$19.8K Buy
+5,800
New +$26.6K 0.01% 685

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Catalyst Funds Management's SGMT Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 13,900 shares worth $72.6K. The stake represents 0.01% of the portfolio and ranks #514 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in SGMT as recently as Q3 2024.

Catalyst Funds Management first reported a position in SGMT in Q2 2024 and has held it in 3 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Catalyst Funds Management held 13,900 shares of Sagimet Biosciences worth $72.6K as of Q1 2026.
  • Sagimet Biosciences was a new Catalyst Funds Management position in Q1 2026.
  • Sagimet Biosciences made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #514 holding.
  • Catalyst Funds Management first reported a position in Sagimet Biosciences in Q2 2024 and has held it in 3 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.